Introduction: Evidences for antipsychotics augmentation for schizophrenic patients with suboptimal efficacy have been lacking although it has been widespread therapeutic strategy in clinical practice. Objectives: The purpose of this study was to investigate the efficacy and tolerability of blonanserin augmentation with an atypical antipsychotics (AAPs) in schizophrenic patients Methods: A total of 100 patients with schizophrenia partially or completely unresponsive to treatment with an AAP recruited in this 12-week, open-label, non-comparative, multicenter study. Blonanserin was added to existing AAPs which were maintained during the study period. Efficacy was primarily evaluated using Positive and Negative Syndrome Scale (PANSS) at baseline, week 2, 4, 8, and 12. Predictors for PANSS response (≥20% reduction) was investigated. Results: The PANSS total score was significantly decreased at 12 weeks after blonanserin augmentation (-21.0 ± 18.1, F=105.849, p<0.001). Response rate on PANSS at week 12 was 51.0%. Premature discontinuation was occurred in 17 patients (17.0%) and 4 patients among them discontinued the study due to adverse events. Nine patients experienced significant weight gain during the study. Response to blonanserin augmentation was associated with severe (PANSS>85) baseline symptom (OR=10.298, p=0.007) and higher dose (>600mg/day of chlorpromazine equivalent dose) of existing AAPs (OR=4.594, p=0.014). Conclusions: Blonanserin augmentation improved psychiatric symptoms of schizophrenic patients in cases of partial or non-responsive to an AAP treatment with favorable tolerability. Patients with severe symptom despite treatment with higher dose of AAP were benefited from this augmentation. These results suggested that blonanserin augmentation could be an effective strategy for specific patients with schizophrenia. Keywords: Blonanserin · Schizophrenia · Augmentation · Treatment response · Antipsychotics Korea, 62, Yeouidodong, Yeoungdeungpogu, Seoul, 
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Inpatient mortality and occurrence of re-hospitalization due to cardiovascular diagnosesfollowing acute myocardial infarction in patients with or without serious mental illness Abstract Objective: People with serious mental illness (SMI, including schizophrenia and bipolar disorder) experience adverse health and premature mortality. Higher incidence and/or worse outcome of acute myocardial infarction (AMI) may partly underlie this. We aimed to compare inpatient mortality and occurrence of re-hospitalization due to cardiovascular diagnoses following AMI in patients with and without SMI. Method: A historic cohort was conducted using the Taiwan National Health Insurance Research Database. Inpatient mortality and rates of readmission from adult patients with diagnoses of schizophrenia or bipolar disorder that had the first episode of AMI receiving invasive coronary procedures were compared to general population controls.Outcomes of inpatient mortality and occurrence of re-hospitalization were compared in logistic regression models. Results: A total of 3,361 adult patients with incident AMI between 1996 and 2007 were identified, of whom 591 (17.6%) and 243 (7.2%) had a diagnosis of schizophrenia and bipolar disorder respectively, with 2,527 controls. The mean (SD) age at recorded AMI was 57.1 (15.4) years for people with schizophrenia, 64.2 (15.4) years in people with bipolar disorder, and 66.8 (13.8) years in the comparison cohort. In these patients with AMI, two thirds of the patients were male. Inpatient mortality was 2-folds higher in patients with schizophrenia compared to controls (Odds ratio: 2.79 (1.87 ~ 4.17, p<0.001); but not in bipolar disorder. There were no significant elevations in the odds of re-admissions due to second AMI episode or due to heart failure in patients with psychiatric diagnosis. However, the odds of readmission due to cardiogenic shock were significantly higher in psychiatric groups after adjustment (Odds ratios: 2.29 (1.48 ~ 3.55), p<0.001 for schizophrenia; and 1.80 (1.14 ~ 2.83), p<0.01 for bipolar disorder). Conclusion: Schizophrenia was associated with raised risk of inpatient mortality following an AMI episode. However, rate of re-admission due to cardiogenic shock was significantly higher in patients with SMI. Potential public health and clinical implications were discussed
